Guangdong Proposes 13 New Medical Service Fees Including Alzheimer's Biomarker Testing; Private Hospital Group Launches $1.7B Medtech R&D Project

1. Henan Provincial Drug Administration and Zhengzhou Airport Economic Zone Sign Strategic Agreement

Recently, the Signing Ceremony for Empowering High-Quality Development of Biomedical Industry in Zhengzhou Airport Economy Zone was Launched at the International Conference Center of Yuanbo Garden in Zhengzhou Airport Area, Henan Province. At the event, the Henan Provincial Drug Administration signed a strategic cooperation agreement with the Management Committee of Zhengzhou Airport Area to jointly promote the high-quality development of the biomedical industry. According to the memorandum of cooperation, both parties will focus on five key areas: developing characteristic parks such as cell and gene therapy, conducting pilot projects for pharmaceutical e-commerce; introducing pharmaceutical manufacturing enterprises and supporting companies in establishing research institutions; building digital financial platforms and drug marketing authorization holder funds; hosting international biomedicine expos and cultivating "Henan-produced traditional Chinese medicine" blockbuster products; innovating regulatory mechanisms like the "whitelist supervision." (China News Service Henan)

2. The Ministry of Finance Allocates Comprehensive Reform Subsidy Funds for Public Hospitals

Recently, the Ministry of Finance issued the "Notice of the Ministry of Finance and the National Health Commission on the Allocation of the 2025 Medical Services and Capacity Improvement (Comprehensive Reform of Public Hospitals) Subsidy Fund (Second Batch) Budget." The fund is intended to support the implementation of demonstration projects for public hospital reform and high-quality development, further deepen comprehensive reforms in public hospitals, and promote their high-quality development. This financial subsidy provides 100 million yuan for each demonstration project, totaling 2 billion yuan. The key focus areas of the public hospital reform and high-quality development demonstration projects include enhancing the diagnostic capabilities of municipal and county-level public hospitals, accelerating the construction of a tiered medical system; controlling unreasonable increases in medical costs and deepening comprehensive reforms in public hospitals; strengthening smart hospital construction and driving information technology-enabled reform and high-quality development in public hospitals. The project implementation cycle is three years, with a cumulative amount of central government funding not exceeding 500 million yuan. (NetEase News)

3. Guangdong Plans to Add 13 New Charges Including AD

Recently, the official website of Guangdong Provincial Medical Insurance Bureau released a public announcement for soliciting opinions on the addition and revision of medical service price projects by the Guangdong Provincial Medical Security Bureau, including "Minimal Residual Disease Testing for Multiple Myeloma" and others. Among these, 13 new testing-related service charges were added, such as minimal residual disease testing for multiple myeloma, Alzheimer's disease-related protein testing, high-sensitivity human immunodeficiency virus ribonucleic acid amplification quantitative measurement, etc. It is proposed to modify the Down syndrome screening - fetal trisomy 21 syndrome genetic testing screening project to non-invasive prenatal genetic testing for fetal chromosomal aneuploidy, with a charge of 560 yuan. The details of the Alzheimer's disease-related protein testing project are as follows: By detecting human β-amyloid 1-42, human β-amyloid 1-40, human phosphorylated tau-181, human phosphorylated tau-217, neurofilament light chain (NfL) protein, etc., in the blood, it provides auxiliary diagnostic evidence for early Alzheimer's disease and risk assessment. (IVD Professionals Network)

4. Sunnyou Launches 13 Brain-Computer Interface Devices

Recently, the 2025 Henan Brain-Computer Interface Technology Innovation and Development Forum, the Hongqiqu Brain-Computer Interface Rehabilitation Science Forum, and the National Key Research and Development Program "Brain-Limb Fusion" Brain Function Reconstruction Technology Seminar opened. At the opening ceremony, the Brain-Computer Interface Rehabilitation Technology Innovation Consortium, led by Sunnyou and jointly established with 14 top research institutions and clinical units, held its inauguration启动仪式. Meanwhile, Sunnyou held the launch ceremony for its Global New Product Release of brain-computer interface technology, unveiling five series comprising 13 brain-computer interface devices, which became the center of attention due to several technological breakthroughs. According to reports, the five series of products are: the Brain-Computer Interface PT (Physical Therapy) Movement Therapy Solution, the Brain-Computer Interface OT (Occupational Therapy) Rehabilitation Solution, the Brain-Computer Interface ST (Swallowing and Cognitive) Solution, the Neurorehabilitation Electrical Stimulation Biofeedback Treatment System in the Brain-Computer Interface Physical Factor Series, and the Brain-Computer Interface Intelligent Rehabilitation Care Solution. (China Securities Journal)

5. Private Hospital's 1.2 Billion Medical Device R&D and Production Project Commences

Recently, the high-end medical device R&D, production, and listing headquarters project of Suzhou Ruixing Orthopedic Hospital Group Co., Ltd. officially commenced in Wuzhong District. Ruixing is not a traditional medical device company but a private hospital group founded by doctors. More precisely, it is a doctor group that started in the fields of hand surgery and orthopedics. Ruixing Group is a hospital group with core businesses in hospital investment, hospital management, hospital management technology consulting, training, medical diagnosis and treatment, and medical scientific research. The group focuses on four functional sectors: healthcare, pharmaceuticals, biomanufacturing, and hospital services, establishing a discipline development pattern featuring hand surgery, trauma orthopedics, and rehabilitation medicine. Ruixing Group has entered the IPO coaching stage, and its listing plan is proceeding steadily. It is reported that the project, located in Wuzhong Biomedical Industrial Park, covers an area of approximately 22.9 mu, with a total investment of 1.2 billion yuan and a planned construction area of about 50,000 square meters, aiming to build Ruixing Group's high-end medical device R&D, production, and listing headquarters. (Medical Device Distributors Alliance)

6. Nerveblox Receives FDA Approval

Recently, Nerveblox, the artificial intelligence software solution from Turkey's SmartAlpha company, successfully obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA). Specifically designed for ultrasound applications in regional anesthesia procedures, Nerveblox has brought about a qualitative leap in the precision of nerve block surgeries. It acts like an indefatigable "super assistant," capable of rapidly detecting and highlighting up to 50 critical anatomical structures during ultrasound scans. Whether it’s hidden nerves, delicate and complex blood vessels, or surrounding muscles, bones, and other tissues, nothing escapes its "keen eye." During actual surgeries, as doctors use ultrasound probes to scan the surgical area of patients, Nerveblox quickly analyzes the ultrasound images and clearly marks key anatomical structures in a highly visible manner—possibly using different colors for distinction or providing concise textual descriptions—offering doctors an immediate and clear understanding. This greatly enhances the accuracy and safety of the procedures. (CCI Cardiovascular Doctors Innovation Club)

7. R&D Design Services Accelerate the Clinical Transformation of Medical Research Achievements

The research and development of medical devices is a complex and rigorous process, involving multiple aspects such as technology, regulations, and clinical practices. Orschda boasts a 20,000-square-meter science and innovation center and has established a Medical Device Research Institute dedicated to the clinical transformation of medical scientific research achievements. It possesses a high-level, international, multidisciplinary professional team proficient in the entire process of R&D, regulations, clinical trials, registration, and production, capable of conducting R&D and production for various complex and innovative products. The company has accumulated extensive project experience and industry resources, establishing a standardized, regulated, and digitalized full-process service system. It provides one-stop services ranging from preliminary market research, product concept generation, product design and development to prototype production and testing. To date, Orschda has had over 200 projects enter the review stage, with more than 100 projects currently under development, achieving a 100% success rate in transformation. (Orschda compilation)

8. Huapeng Boron Neutron Completes Pre-A Round Financing Worth Hundreds of Millions

Recently, China Boron Neutron Technology Co., Ltd. announced the completion of a Pre-A round of financing worth hundreds of millions of RMB. This round was jointly led by Wuchan Zhongda Hongcheng Investment and its affiliates (Taizhou Circular Economy, Zhegu Group, Huadian Investment) along with Kaitai Capital, with participation from Huzhou Industrial Investment, Anfeng Venture Capital, and Caitong Capital. The funds will mainly be used to accelerate clinical trial research, the development of new boron drugs, and the commercial promotion and implementation of BNCT equipment, injecting strong momentum into the rapid development of China Boron Neutron in the BNCT field. Established in 2023, China Boron Neutron Technology Co., Ltd. is a national high-tech enterprise specializing in the design, development, manufacturing, and promotion of accelerator-driven boron neutron capture therapy technology products. (Investment界)